For millions living with chronic obstructive pulmonary disease (COPD) and asthma, inhalers are a lifeline. But that convenience comes with a hidden cost: a significant impact on the environment. Latest research from UCLA Health suggests that switching to certain types of inhalers could not only reduce that carbon footprint but may also offer slightly improved health outcomes for patients. The study, published today in JAMA Internal Medicine, adds to a growing body of evidence highlighting the environmental impact of healthcare and the potential for more sustainable practices.
The core of the issue lies in the propellant used to deliver medication to the lungs. Many commonly prescribed inhalers, known as metered-dose inhalers (MDIs), rely on hydrofluoroalkane (HFA) propellants – potent greenhouse gases also found in older aerosol sprays. Researchers found that MDIs generated over 2 million metric tons of carbon emissions annually over the past decade, equivalent to the emissions of roughly 530,000 gas-powered cars each year. This makes inhalers a surprisingly significant contributor to the healthcare system’s overall environmental impact.
Lower-Emission Alternatives Present Promise
The UCLA Health study focused on a specific class of inhalers used to treat COPD – those combining a long-acting muscarinic antagonist (LAMA) and a long-acting beta agonist (LABA). Researchers compared the clinical outcomes and environmental impact of MDIs within this class to those of dry powder inhalers (DPIs) and soft mist inhalers (SMIs). DPIs and SMIs deliver medication without the need for propellants, significantly reducing their global warming potential.
The findings revealed a subtle but potentially important benefit to the lower-emission options. Patients using the dry powder inhaler, umeclidinium-vilanterol, experienced a 14% lower risk of moderate or severe COPD exacerbations – sudden worsening of symptoms – compared to those using the MDI, glycopyrrolate-formoterol. Similarly, the soft mist inhaler, tiotropium-olodaterol, was associated with a 6% lower risk of exacerbations compared to its metered-dose counterpart. Importantly, the study found no meaningful differences in safety outcomes across the groups, with no increased risk of major cardiovascular events, urinary tract infections, or pneumonia.
A Growing Body of Evidence
This isn’t the first indication that dry powder inhalers may offer advantages beyond environmental benefits. Dr. William Feldman, a pulmonologist and health services researcher at UCLA Health and the study’s senior author, noted that his team previously published research in BMJ demonstrating similar positive outcomes with DPIs in another COPD medication class. “These findings highlight the opportunity to reduce healthcare-related emissions even as potentially improving patient care,” Dr. Feldman said.
The research team analyzed insurance claims data from over 40,000 adults aged 40 and older newly prescribed one of the three inhaler types between 2016 and 2025. Patients were continuously enrolled in either a large commercial or Medicare Advantage health plan, allowing researchers to track their health outcomes over time and compare the effectiveness and safety of each inhaler type.
Understanding COPD and Inhaler Options
COPD, a progressive lung disease that makes it hard to breathe, affects millions of Americans. According to the Centers for Disease Control and Prevention, an estimated 16.4 million Americans have COPD, and it’s a leading cause of death in the United States. Inhalers are a cornerstone of COPD management, delivering medication directly to the airways to open them up and ease breathing.
The three main types of inhalers are:
- Metered-Dose Inhalers (MDIs): These use a propellant to deliver a measured dose of medication.
- Dry Powder Inhalers (DPIs): These deliver medication in a dry powder form, requiring a strong, quick inhalation.
- Soft Mist Inhalers (SMIs): These create a slow-moving mist, making it easier for patients to inhale the medication.
What This Means for Patients and the Future of Respiratory Care
While the differences in clinical outcomes observed in the UCLA Health study were modest, researchers emphasize the importance of considering both patient health and environmental impact when choosing an inhaler. “Although some patients may require MDIs, dry powder inhalers and soft mist inhalers are a safe and effective option for most patients with COPD,” Dr. Feldman explained. The study reinforces the idea that small changes in healthcare practices can collectively contribute to a more sustainable future.
Looking ahead, Dr. Feldman’s team plans to continue investigating the environmental impact of different medications and healthcare technologies. Further research will be crucial to identify additional opportunities to reduce the carbon footprint of the healthcare system while maintaining – and potentially improving – patient care. The next step involves exploring the feasibility of wider adoption of lower-emission inhalers and addressing any potential barriers to access or patient preference.
Disclaimer: This article provides general information and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have thoughts on this story? Share your comments below and consider sharing this article with your network.
